SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: BMcV who wrote (3824)10/27/1999 10:19:00 AM
From: sam  Respond to of 10280
 
LEHM: Reit strong buy on SEPR -- major milestone -- target 145. Eat your heart out Jordan!



To: BMcV who wrote (3824)10/27/1999 2:08:00 PM
From: M. Ramle  Read Replies (1) | Respond to of 10280
 
Bruce:

There is a very interesting article in today's issue of the Boston Globe about Xopenex. Go to boston.com and enter "Health" topic to get access to that article. Maybe (just maybe) the FDA would eventually wake up and decides to pull Albuterol from the market, giving SEPR the lion's share. Good Luck.

Mazen



To: BMcV who wrote (3824)10/27/1999 4:19:00 PM
From: Bob Swift  Read Replies (1) | Respond to of 10280
 
Bruce,
There is the nagging question of how much better is Claritin 2 versus 1. This determines how successful the switching will be. SGP has so far refused to comment on the data citing regulatory reason. Hopefully if and when Claritin 2 fails, Nori will take its place and we actually get a bigger piece of the pie.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News